Comparative study of centrally acting muscle relaxants in spasticity associated with post stroke celebral palsy and spinal cord injury

dc.contributor.guidePatel Bhoomika M
dc.coverage.spatial
dc.creator.researcherAgarwal Saurabh
dc.date.accessioned2018-03-15T10:07:53Z
dc.date.available2018-03-15T10:07:53Z
dc.date.awarded06/11/2017
dc.date.completed28/08/2017
dc.date.registered12/03/2011
dc.description.abstractSpasticity is a clinical sign of upper motor neuron dysfunction. It occurs due to defects in inhibitory descending spinal motor pathways. The aim of the treatment of spasticity is to facilitate rehabilitation, increase daily activities, prevent contractures and relieve pain. Nowadays, physiotherapy is becoming a very common practice in the rehabilitative management of spasticity. Stretching can increase the extensibility of soft tissues by a mechanism that involves viscous deformation and structural adaptations of muscle and other soft tissues. Oral baclofen is one of the most common drug used for the treatment of spasticity on a long term basis. It has been reported that baclofen causes reduction in hyperreflexia, muscle tone and contractions of paraylzed muscles. The muscle activity reductions though suggest induction of long-term disuse effects in muscle by baclofen. Infact, it has been reported that patients with SCI or multiple sclerosis have complaints of muscle weakness and reduced voluntary functions after few weeks. In the past two decades, BTX-A has been introduced with an aim to reduce spasticity in children with CP. The benefits of BTX-A treatment include a reduction in muscle tone, increased joint ROM, improved gait patterns, and functional improvements. There is a known association between the use of BTX-A and muscle weakness, with reports of generalised muscle weakness and weakness in neighbouring non-targeted muscles. From last few years, tolperisone has presented itself as a very effective and safe muscle relaxant in all types of spasticities. Tolperisone has different pharmacological properties than other myotonolytic agents viz. absence of sedation or withdrawal phenomenon. Only few studies are available evaluating the safety and efficacy profile of tolperisone in post-stroke spasticity and no reports are available for SCI and CP related spasticity. newline
dc.description.note
dc.format.accompanyingmaterialDVD
dc.format.dimensions
dc.format.extent
dc.identifier.urihttp://hdl.handle.net/10603/195967
dc.languageEnglish
dc.publisher.institutionInstitute of Pharmacy
dc.publisher.placeAhmedabad
dc.publisher.universityNirma University
dc.relation
dc.rightsuniversity
dc.source.universityUniversity
dc.subject.keywordcerebral palsy
dc.subject.keywordcord
dc.subject.keywordhyperreflexia
dc.subject.keywordpharmacy
dc.subject.keywordspasticity
dc.subject.keywordspinal
dc.subject.keywordstroke
dc.titleComparative study of centrally acting muscle relaxants in spasticity associated with post stroke celebral palsy and spinal cord injury
dc.title.alternative
dc.type.degreePh.D.

Files

Original bundle

Now showing 1 - 5 of 13
Loading...
Thumbnail Image
Name:
10_chapter2.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Description:
Attached File
Loading...
Thumbnail Image
Name:
11_chapter3.pdf
Size:
401.26 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
12_chapter4.pdf
Size:
944.01 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
13_chapter5.pdf
Size:
320.44 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
14_summary&conclusion.pdf
Size:
156.16 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description: